IRISeq: A New Technology for Mapping Brain Aging at Single-Cell Resolution

Every five years, the field of aging research undergoes a technological upheaval. Once it was DNA sequencing, then methylation and epigenetic clocks, then single-cell RNA sequencing (scRNA-seq). Now we are in the midst of another revolution: spatial genomics, the ability to know not only which genes are active in a cell, but exactly where that cell sits within the tissue, who its neighbors are, and what it signals to them.

The problem: until now, spatial mapping required specialized microscopes, cameras costing half a million dollars, and labs with heavy optical infrastructure. Most labs in the world, and certainly most labs in Israel, could not afford it. And this is where the new study published in Nature on May 12, 2026, comes in.

An international group of researchers presents a new method called IRISeq (Indexed Reverse-transcription In-situ Sequencing), an optics-free method that achieves the same spatial result without a microscope and without an expensive imaging system. They apply it to mouse and human brains of different ages, revealing the brain aging map at a resolution we have never seen before.

What is Spatial Genomics Anyway?

In regular RNA sequencing, we take tissue, break it down into individual cells, and ask: which genes are active in each cell? The result: a list of cells with a gene expression profile. But we lost the location information. Where was the cell? Who were its neighbors? What passed between them?

• Spatial genomics solves the problem: it measures gene expression while preserving the original coordinates of each cell in the tissue.
• This is critical in the brain, an organ where every function is based on architecture: layers in the cortex, nuclei in the hippocampus, connectivity pathways.
• Existing technologies (10x Genomics' Visium, Vizgen's MERFISH) require specialized fluorescence cameras, imaging platforms, and expert teams.
• The cost per experiment: $5,000 to $15,000 per tissue section, not including the cost of the equipment.
• The result: only about 200 labs worldwide had used spatial genomics extensively by 2025.

What IRISeq Does Differently

The new method uses a different physical principle. Instead of seeing the fluorescent signal under a microscope, it encodes the location within the DNA sequence itself. Each cell in the tissue receives a unique barcode representing its coordinates, and when standard sequencing (regular Illumina) is run, the sequence itself tells both which genes were expressed and where the cell was located.

Advantages:

• No microscope needed. Any lab with a standard sequencing machine can run the experiment.
• Cost drops by an order of magnitude: from $10,000 to about $800 per section.
• Shorter run time: a day instead of a week.
• Single-cell resolution, sometimes even subcellular resolution.
• Preservation of the three-dimensional architecture of the tissue.

This is true democratization: the technology becomes accessible to medium-sized academic labs, university hospitals, and developing countries. Expect a significant increase in spatial genomics studies in the next five years.

Current Evidence

Study 1: Mapping Mouse Cortex with IRISeq, 2026

The researchers mapped the cortex of 3-month-old (young) mice versus 24-month-old (old, equivalent to 70-80 in humans) mice. They identified 74 different cell subtypes and measured gene expression in each. The key finding: not all neuron types age at the same rate. Pyramidal neurons in layer 5 (responsible for motor coordination and executive functions) showed the most extreme decline, with 40% less expression of synaptic genes.

Study 2: Hippocampus and Memory Traces

The hippocampus, the brain region responsible for memory, was also mapped. The researchers found that granule cells in the Dentate Gyrus (the area that produces new neurons even in adulthood) lose the ability to express neurogenesis genes as early as 12 months in mice, equivalent to age 40 in humans. This precedes clinical symptoms by decades.

Study 3: Glial Cells and Local Inflammation

The most surprising finding: glial cells, especially microglia and astrocytes, are the main drivers of brain aging, not neurons. Using IRISeq, they identified local inflammatory hotspots where aged microglia secrete inflammatory cytokines (IL-6, TNF-alpha) and affect neighboring neurons. 43% of cognitive decline is linked to these areas.

Study 4: Human Brain, Post-Mortem

The group also applied IRISeq to human brain samples, including individuals who died at ages 25, 55, and 85. They found patterns very similar to mice: certain neurons lose function, glial cells become inflammatory, and there are senescence markers (zombie cells) in specific areas of the prefrontal cortex. This is the area responsible for decision-making and working memory.

What Implications Does This Have for Aging Research?

The ability to map brain aging at such resolution opens new doors:

• Identifying precise drug targets: if 43% of cognitive decline comes from local microglial inflammatory areas, drugs can be developed that target exactly those cells.
• Early detection of dementia: if neurogenesis in the Dentate Gyrus declines 40 years before symptoms, preclinical tests can be developed.
• Testing interventions: senolytics (fisetin, quercetin), rapamycin, metformin, intermittent fasting. All interventions claiming to slow brain aging can now be tested precisely, region by region.
• Comparison across species: why do mice age at a 1:30 rate compared to humans? Which cells age faster?

Should We Be Excited?

The technology is impressive, but there are important limitations:

• It is still an experimental method. It needs 2-3 years of validation in independent labs before becoming a standard.
• Bioinformatic analysis is complex. Each experiment generates terabytes of data requiring specialized expertise to decode.
• Resolution is not everything. Knowing which gene is expressed where does not mean you understand causality. Functional experiments are still needed.
• Humans are only post-mortem. There is no way to map a living human brain. All clinical implications go through observing mouse brains and comparing to limited human data.
• Cost is still significant. Even $800 per section is a lot when you want to map thousands of samples.

Additionally, it is important to understand: this is a tool, not a drug. IRISeq will not slow aging; it only helps us understand it. Clinical interventions still need to be developed separately.

What Can You Take from the Study Today?

1. Brain aging starts very early. If neurogenesis in the Dentate Gyrus is already declining at age 40, start today building habits that protect the brain: quality sleep, physical activity, continuous learning.
2. Inflammation is the main enemy. Aged glial cells secrete inflammatory cytokines. An anti-inflammatory diet (Mediterranean or MIND diet), avoiding sugar and saturated fat, and treating dental issues (linked to systemic inflammation) help.
3. Regular aerobic activity reduces microglial inflammation and stimulates neurogenesis. 150 minutes per week is the minimum.
4. Deep sleep is critical. The glymphatic system clears brain toxins only during deep sleep. 7-9 hours, a dark room, no screens an hour before.
5. Continuous cognitive stimulation. Learning a new language, musical instrument, or complex skill builds cognitive reserve. Granule cells are activated only when they have a task.
6. Follow the research. In the next five years, expect new drugs targeting the local inflammatory areas identified by IRISeq.

The Broader Perspective

The IRISeq story is an excellent example of the development of aging research over the past decade. We have moved from measuring lifespan, to identifying genes, to mapping methylation, to single-cell sequencing, and now to three-dimensional maps of whole tissues. Each such leap opens a wider window on how the body ages.

The more important lesson: aging is not a uniform event. It is a heterogeneous, local, cell-type-specific process. One area of your brain may age at twice the rate of another. Glial cells may lead the process before neurons suffer. And your actions, what you eat, sleep, and think, affect each area differently.

In a decade, you might walk into a clinic, undergo a personal brain scan, and receive an intervention plan tailored to the areas aging fastest in you. The tools building this future are being created now, and IRISeq is one of them. Aging is not a decree of fate; it is a process that can be measured, understood, and changed.

References:
Nature, 2026: Optics-free spatial genomics for mapping mammalian brain aging by IRISeq